New perspectives in the treatment of neuroendocrine tumours.
The treatment of neuroendocrine tumours (NETs) is mainly based on their biological characteristics of aggressiveness and functional features. Radical surgery is the sole effective approach. In other types of well-differentiated tumours, hormonal therapy is the treatment of choice, as well as chemotherapy is the treatment of choice for aggressive diseases. Recent advances in the field of targeted therapies have expanded options for NETs, particularly of pancreatic neuroendocrine tumours. The radiotherapy option in NETs is based on radiopharmaceuticals targeting receptors over-expressed by these diseases and acting on the cell metabolism.
Institute of Oncology – Policlinico of Monza, Monza, Italy. emilio.bajetta@policlinicodimonza.it
Emilio
E
Bajetta
Laura
L
Catena
Monica
M
Valente
Nadia
N
Bianco
Fernanda
F
Bellomo
Emilio
E
Bombardieri
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D003131:Combined Modality Therapy; D006801:Humans; D018358:Neuroendocrine Tumors / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D011878:Radiotherapy; D016032:Randomized Controlled Trials as Topic; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013004:Somatostatin